Last reviewed · How we verify
rhFSH
rhFSH (recombinant human follicle-stimulating hormone) stimulates the growth and maturation of ovarian follicles in women by binding to FSH receptors on granulosa cells.
rhFSH (recombinant human follicle-stimulating hormone) stimulates the growth and maturation of ovarian follicles in women by binding to FSH receptors on granulosa cells. Used for Infertility in women undergoing assisted reproductive technology (ART), Anovulation and ovulatory disorders in women.
At a glance
| Generic name | rhFSH |
|---|---|
| Sponsor | Fundación Santiago Dexeus Font |
| Drug class | Gonadotropin |
| Target | FSH receptor (FSHR) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
rhFSH is a recombinant form of the naturally occurring pituitary hormone follicle-stimulating hormone. It acts on FSH receptors in the ovary to promote follicular development and estrogen production, essential for ovulation. This mechanism is used therapeutically to induce controlled ovarian hyperstimulation in assisted reproductive technologies.
Approved indications
- Infertility in women undergoing assisted reproductive technology (ART)
- Anovulation and ovulatory disorders in women
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Headache
- Injection site reactions
- Abdominal pain/bloating
- Nausea
Key clinical trials
- Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome (PHASE1)
- PErsonalized Addition of Recombinant LH in Ovarian Stimulation (PHASE4)
- Randomized Controlled Study of Comparing Follitrope Versus Gonal-f in Chinese Infertility Women. (PHASE3)
- Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART) (PHASE3)
- Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET (PHASE3)
- Monitoring the Early Follicular Phase With Androstenedione in Low-dose Step-up Ovulation Induction in High Responders
- To Describe the Effect of rhLH Supplementation in Women With Hyporesponse to rhFSH After Pituitary Downregulation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rhFSH CI brief — competitive landscape report
- rhFSH updates RSS · CI watch RSS
- Fundación Santiago Dexeus Font portfolio CI